Advertisement

Antihypertensive Agents: Mechanisms of Drug Action

  • Bernard Waeber
  • Hans R. Brunner
Part of the Atlas of Heart Diseases book series (AD)

Abstract

Hypertension is a major risk factor for the development of cardiovascular diseases. There is a direct relationship between blood pressure and the incidence of stroke and coronary events [1]. Even modest elevations in blood pressure (both systolic and diastolic) are associated with an increased health risk. Hypertension also predisposes to left ventricular hypertrophy and chronic renal failure [2, 3].

Keywords

Vascular Smooth Muscle Cell Calcium Antagonist Total Peripheral Resistance Ethacrynic Acid Distal Convoluted Tubule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mac Mahon S, Peto R, Cutler J, et al.: Blood pressure, stroke, and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression, dilution bias. Lancet 1990, 335: 765–777.PubMedCrossRefGoogle Scholar
  2. 2.
    Frohlich ED, Apstein C, Chobanian AV, et al.: The heart in hypertension. N Engl J Med 1992, 327: 998–1007.PubMedCrossRefGoogle Scholar
  3. 3.
    Whelton PK, Klag MJ: Hypertension as a risk factor for renal disease: review of clinical and epidemiological evidence. Hypertension 1989, 13(suppl 1): 19–27.CrossRefGoogle Scholar
  4. 4.
    Collins R, Peto R, Mac Mahon S, et al.: Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990, 335: 827–838.PubMedCrossRefGoogle Scholar
  5. 5.
    Mac Mahon S, Rodgers A: The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993, 15: 967–978.PubMedCrossRefGoogle Scholar
  6. 6.
    The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157: 2413–2446.Google Scholar
  7. 7.
    Chalmers J: The 1999 WHO-ISH guidelines for the management of hypertension. Med J Aust 1999, 171(9): 458–459.PubMedGoogle Scholar
  8. 8.
    Brunner HR, Gavras H: Clinical implications of renin in the hypertensive patient. JAMA 1975, 233: 1091–1093.PubMedCrossRefGoogle Scholar
  9. 9.
    Folkow B: Sympathetic nervous control of blood pressure: role in primary hypertension. Am J Hypertens 1989, 2: 103S–111S.PubMedGoogle Scholar
  10. 10.
    Muntzel M, Drücke: A comprehensive review of the salt and blood pressure relationship. Am J Hypertens 1992, 5: 1S–42S.PubMedGoogle Scholar
  11. 11.
    Chalmers J: The place of combination therapy in the treatment of hypertension in 1993. Clin Exp Hypertens 1993, 15: 1299–1313.PubMedCrossRefGoogle Scholar
  12. 12.
    Brunner HR, Ménard J, Waeber B, et al.: Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and fixed-dose combinations. J Hypertens 1990, 8: 3–11.PubMedCrossRefGoogle Scholar
  13. 13.
    Ménard J: Critical assessment of combination therapy development. Blood Pressure 1993, 2(suppl 1): 5–9.Google Scholar
  14. 14.
    Johnston CI: The place of diuretics in the treatment of hypertension in 1993: can we do better? Clin Exp Hypertens 1993, 15: 1239–1255.PubMedCrossRefGoogle Scholar
  15. 15.
    Puschett JB: Diuretics in hypertension. In Cardiovascular Pharmacology and Therapeutics. Edited by Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL. New York: Churchill Livingstone; 1994: 885–908.Google Scholar
  16. 16.
    Blaustein MP: Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment of a hypothesis. Am J Physiol 1977, 232: 165–173.Google Scholar
  17. 17.
    Tarazi RC, Dustan HP, Frohlich ED: Long-term thiazide therapy in essential hypertension. Circulation 1970, 41: 709–717.PubMedCrossRefGoogle Scholar
  18. 18.
    Lefkowitz RJ: ß-adrenergic receptors: recognition and regulation. N Engl J Med 1976, 295: 323–328.PubMedCrossRefGoogle Scholar
  19. 19.
    Franca G, Nies AS: ß-adrenergic blockers in the treatment of hypertension. In Cardiovascular Pharmacology and Therapeutics. Edited by Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL. New York: Churchill Livingstone; 1994: 945–956.Google Scholar
  20. 20.
    Man in’t Veld AJ, van den Meiracker A, Schalekamp MADH: The effect of ß-blockers on total peripheral resistance. J Cardiovasc Pharmacol 1986, 8(suppl 4): 49–60.CrossRefGoogle Scholar
  21. 21.
    Lund-Johansen P: Hemodynamic changes at rest and during exercise in long-term Clonidine therapy of essential hypertension. Acta Med Scand 1974, 195: 111–115.PubMedCrossRefGoogle Scholar
  22. 22.
    Oparil S, Haber E: The renin-angiotensin system. N Engl J Med 1974, 291: 389–401.PubMedCrossRefGoogle Scholar
  23. 23.
    Dzau VJ, Re R: Tissue angiotensin system in cardiovascular medicine. Circulation 1994, 89: 493–498.PubMedCrossRefGoogle Scholar
  24. 24.
    van Lutterotti N, Catanzaro DF, Sealy JE, Laragh JH: Renin is not synthesized by cardiac and extrarenal vascular tissues: a review of experimental evidence. Circulation 1994, 89: 458–470.CrossRefGoogle Scholar
  25. 25.
    Waeber B, Nussberger J, Juillerat L, Brunner HR: Angiotensin converting enzyme inhibition: discrepancy between antihypertensive effect and suppression of enzyme activity. J Cardiovasc Pharmacol 1989, 14(suppl 4): 53–59.CrossRefGoogle Scholar
  26. 26.
    Carretero OA, Scicli AG: Local hormonal factors (intacrine, autocrine, and paracrine) in hypertension. Hypertension 1991, 18(suppl I): 58–69.CrossRefGoogle Scholar
  27. 27.
    Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991, 43: 109–142.PubMedGoogle Scholar
  28. 28.
    Vanhoutte PM: Other endothelium-derived vasoactive factors. Circulation 1993, 87(suppl V): 9–17.Google Scholar
  29. 29.
    Zimmerman BG, Sybert EG, Wong PC: Interaction between sympathetic and renin-angiotensin system. J Hypertens 1984, 2: 581–588.PubMedCrossRefGoogle Scholar
  30. 30.
    Brunner HR, Gavras H, Waeber B: Enhancement by diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockade. Clin Exp Hypertens 1980, 2: 639–657.PubMedCrossRefGoogle Scholar
  31. 31.
    Luft FC, Haller H: Calcium channel blockers in current medical practice: an update for 1993. Clin Exp Hypertens 1993, 15: 1263–1276.PubMedCrossRefGoogle Scholar
  32. 32.
    Weber MA, Graettinger WF: Calcium channel blockers as hypotensive agents. In Cardiovascular Pharmacology and Therapeutics. Edited by Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL. New York: Churchill Livingstone; 1994: 931–943.Google Scholar
  33. 33.
    Tonyz RM, Schiffrin EL: Signal transduction in hypertension: part I. Curr Opin Nephrol Hypertens 1993, 2: 5–16.CrossRefGoogle Scholar
  34. 34.
    Tonyz RM, Schiffrin EL: Signal transduction in hypertension: part II. Curr Opin Nephrol Hypertens 1993, 2: 17–26.CrossRefGoogle Scholar
  35. 35.
    Grimm RH: α1-Antagonists in the treatment of hypertension. Hypertension 1989, 13(suppl I): 131–136.CrossRefGoogle Scholar
  36. 36.
    Brunner HR, Gavras H, Laragh JH, Keenan R: Hypertension in man: exposure of the renin and sodium components using angiotensin II blockade. Circ Res 1974, 34 (suppl 1): 35–43.Google Scholar
  37. 37.
    Timmermans BM, Wong WMPC, Chiu AT, et al.: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45: 205–251.PubMedGoogle Scholar
  38. 38.
    Nakajima M, Hutshinson HG, Fujinaga M, et al.: The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the ATI receptor: Gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995, 92: 10663–10667.PubMedCrossRefGoogle Scholar
  39. 39.
    Munafo A, Christen Y, Nussberger J, et al.: Drug concentration response relationships in normal volunteers after oral administration of losartan (DuP 753, MK 954), an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992, 51: 513–521.PubMedCrossRefGoogle Scholar
  40. 40.
    Nakashima M, Uematsu T, Kosuge K, Kanamur M: Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992, 42: 333–335.PubMedCrossRefGoogle Scholar
  41. 41.
    Morgan JM, Palmisano M, Piraino A, et al.: The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Clin Pharmacol Ther 1997, 61: 35–44.PubMedCrossRefGoogle Scholar
  42. 42.
    Holwerda NJ, Fogari R, Angeli P, et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996, 14: 1147–1151.PubMedCrossRefGoogle Scholar
  43. 43.
    Urata H, Strobel F, Ganten D: Widespread tissue distribution of human chymase. J Hypertens 1994, 12 (suppl 9): 17–22.Google Scholar
  44. 44.
    Lacourcière Y, Lefebvre J, Nakhle G, et al.: Association between cough and angiotensin converting enzyme inhibitory versus angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens 1994, 12: 549–553.Google Scholar
  45. 45.
    Ramsay LE, Yeo WS, on behalf of the Losartan Cough Study Group: Double-blind comparison of losartan, lisinopril and hydrochlorothiazide in hypertensive patients with a previous angiotensin converting enzyme inhibitor-associated cough. J Hypertens 1995, 13(suppl 1): 73–76.CrossRefGoogle Scholar
  46. 46.
    De Fronzo RA: Insulin resistance, hyperinsulinemia, and coronary artery disease: a complex metabolic web. J Cardiovasc Pharmacol 1992, 20(suppl 11): 1–16.CrossRefGoogle Scholar
  47. 47.
    Lithell HOL: Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991, 14: 203–209.PubMedCrossRefGoogle Scholar
  48. 48.
    Neaton JD, Grimm RH, Prineas RJ, et al.: Treatment of mild hypertension study: final results. JAMA 1993, 270: 713–724.PubMedCrossRefGoogle Scholar
  49. 49.
    Folkow B: Physiological aspects of primary hypertension. Physiol Rev 1982, 62: 347–504.PubMedGoogle Scholar
  50. 50.
    Dahlöf B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992, 5: 95–110.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Bernard Waeber
  • Hans R. Brunner

There are no affiliations available

Personalised recommendations